Renal Cell Carcinoma - FOI Response Register

FoI Number
2024-704
Subject
Renal Cell Carcinoma
Date Received
12/02/2025
Request and Response
  1. Does your trust provide SACT (systemic anti-cancer therapy) treatments for Renal Cell Carcinoma? If not, which other trust do you refer Renal Cell Carcinoma patients to for SACT treatments?

 YES

  1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage) :

•           Avelumab + Axitinib

•           Axinitib

•           Cabozantinib

•           Everolimus

•           Lenvatinib + Everolimus

•           Lenvatinib + Pembrolizumab

•           Nivolumab monotherapy

•           Nivolumab + Cabozantinib

•           Nivolumab + Ipilimumab

•           Pazopanib

•           Pembrolizumab monotherapy

•     Pembrolizumab + Axitinib One

•           Radiotherapy only

•           Sunitinib

•           Temsirolimus

•           Tivozanib

•           Other active systemic anti-cancer therapy

•           Palliative care only

NHS Shetland cannot provide indication linked prescribing therefore in accordance with FOISA s 17(1), NHS Shetland confirms that it does not hold the information requested.